Three Strong-buy Stocks Primed for Significant Gains in 2020

The stock market offers so many opportunities. It’s not an easy task to choose stocks worth your while. Lots of futures seem perfectly good at first glance, but not all of them are profitable. To know which one to choose, you must pay close attention to the market’s growth and development, as well as analysts’ recommendations. More often then not, good analysts can predict correctly whether the stock is a strong-buy or not. After all, the main reason for investment is to get a good gain.

Here are three stocks, which Wall Street analysts recommend

Ocular Therapeutix is a biopharma company, which uses a hydrogel platform to develop innovative treatments for various eye diseases. Its DEXTENZA insert has received FDA approval for the treatment of pain and inflammation following ophthalmic surgery. Analysts think that the stock may grow by 57% over the year.

Yi Chen, H.C. Wainwright’s analyst, thinks that the company’s new project will also receive approval from the FDA. Chen raised the price target by $2. The new target at $8 implies that shares could surge 42% over the next year.

Selecta Biosciences is the second strong-buy company. It believes that its ImmTOR immune tolerance platform can help patients fight rare diseases. Selecta Biosciences has already increased by 107% during the last twelve months. Difei Yang, Mizuho Securities analyst, believes that this stock will continue to rise.

Yang stated that the “encouraging” interim data would get the company’s new therapy FDA’s approval. She boosted the price target from $4 to $7. With this new target, the shareholders could gain 66% over the next year.

Lithia Motors, on the other hand, isn’t connected with medicine. It’s one of the largest car retailers in the U.S. This company gained 46% last year. It became the broadest coast-to-coast car retail network in 2019, after expanding its reach to include 92% of the U.S.

Ryan Sigdahl, the Craig-Hallum analyst, stated that though the company experienced some drawbacks recently, it’s still a good investment. He reduced the price target from $200 to $170. nonetheless, the investors could gain 31% with this target over the next year.